Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07ZMQ
|
|||
| Former ID |
DIB006760
|
|||
| Drug Name |
HD-003
|
|||
| Synonyms |
NZ-419; Selective hydroxy radical modulator (chronic kidney disease), Hyundai/ Nippon Zoki
Click to Show/Hide
|
|||
| Indication | Kidney disease [ICD-11: GC2Z] | Phase 2 | [1] | |
| Company |
Nippon Zoki Pharmaceutical Co Ltd
|
|||
| Structure |
 |
Download2D MOL |
||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Hydroxy radical elimination (HYRE) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02378194) Change From Baseline to Chronic Kidney Disease Patient Before and After Administration Drug. U.S. National Institutes of Health. | |||
| REF 2 | Creatinine and HMH (5-hydroxy-1-methylhydantoin, NZ-419) as intrinsic hydroxyl radical scavengers. Drug Discov Ther. 2011 Aug;5(4):162-75. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.